跳至主導覽 跳至搜尋 跳過主要內容

Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 in patients with metastatic breast cancer: phase II randomized, placebo-controlled study

  • Chiun Sheng Huang
  • , Alice L. Yu
  • , Ling Ming Tseng
  • , Louis W.C. Chow
  • , Ming Feng Hou
  • , Sara A. Hurvitz
  • , Richard B. Schwab
  • , James L Murray
  • , Hsien Kun Chang
  • , Hong Tai Chang
  • , Shin Cheh Chen
  • , Sung Bae Kim
  • , Jung Tung Hung
  • , Shir Hwa Ueng
  • , Su Hua Lee
  • , Chwen Cheng Chen
  • , Hope S. Rugo*
  • *此作品的通信作者
  • National Taiwan University
  • Veterans General Hospital-Taipei
  • National Yang Ming Chiao Tung University
  • UNIMED Medical Institute
  • Kaohsiung Medical University
  • University of California at Los Angeles
  • University of California at San Diego
  • University of Texas MD Anderson Cancer Center
  • Chang Gung Memorial Hospital
  • Kaohsiung Municipal United Hospital
  • University of Ulsan
  • OBI Pharma, Inc.
  • National Health Research Institutes Taiwan
  • University of California at San Francisco

研究成果: 期刊稿件 › 文章 › 同儕審查

60 引文 斯高帕斯(Scopus)

摘要

Purpose This randomized, double-blind, placebo-controlled, parallel-group, phase II trial assessed the efficacy and safety of adagloxad simolenin (OBI-822; a Globo H epitope covalently linked to keyhole limpet hemocyanin (KLH)) with adjuvant OBI-821 in metastatic breast cancer (MBC). Methods At 40 sites in Taiwan, USA, Korea, India, and Hong Kong, patients with MBC of any molecular subtype and ≤2 prior progressive disease events with stable/responding disease after the last anticancer regimen were randomized (2:1) to adagloxad simolenin (AS/OBI-821) or placebo, subcutaneously for nine doses with low-dose cyclophosphamide. The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival, correlation of clinical outcome with humoral immune response and Globo H expression, and safety. Results Of 349 patients randomized, 348 received study drug. Patients with the following breast cancer subtypes were included: hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) (70.4%), triple negative (12.9%), and HER2+ (16.7%), similarly distributed between treatment arms. Median PFS was 7.6 months (95% CI: 6.5-10.9) with AS/OBI-821 (n=224) and 9.2 months (95% CI: 7.3-11.3) with placebo (n=124) (HR=0.96; 95% CI: 0.74-1.25; p=0.77), with no difference by breast cancer subtype. AS/OBI-821 recipients with anti-Globo H IgG titer ≥1:160 had significantly longer median PFS (11.1 months (95% CI: 9.3-17.6)) versus those with titers <1:160 (5.5 months (95% CI: 3.7-5.6); HR=0.52; p<0.0001) and placebo recipients (HR=0.71; p=0.03). Anti-KLH immune responses were similar at week 40 between AS/OBI-821 recipients with anti-Globo IgG titer ≥1:160 and those with anti-Globo IgG titer <1:160. The most common adverse events with AS/OBI-821 were grade 1 or 2 injection site reactions (56.7%; placebo, 8.9%) and fever (20.1%; placebo, 6.5%). Conclusion AS/OBI-821 did not improve PFS in patients with previously treated MBC. However, humoral immune response to Globo H correlated with improved PFS in AS/OBI-821 recipients, leading the way to further marker-driven studies. Treatment was well tolerated. NCT01516307.

原文英語
文章編號e000342
期刊Journal for ImmunoTherapy of Cancer
卷8
發行號2
DOIs
出版品狀態已出版 - 22 07 2020

文獻附註

Publisher Copyright:
© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ..All right reserved.

UN SDG

此研究成果有助於以下永續發展目標

  1. SDG3 健康與福祉
    SDG3 健康與福祉

指紋

深入研究「Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 in patients with metastatic breast cancer: phase II randomized, placebo-controlled study」主題。共同形成了獨特的指紋。

引用此